Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Erin E. Burke & Jonathan S. Zager. (2018) Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma. Expert Opinion on Drug Metabolism & Toxicology 14:4, pages 469-473.
Read now
Read now
Kevin J Harrington, Olivier Michielin, Josep Malvehy, Isabella Pezzani Grüter, Lorna Grove, Anna Lisa Frauchiger & Reinhard Dummer. (2017) A practical guide to the handling and administration of talimogene laherparepvec in Europe. OncoTargets and Therapy 10, pages 3867-3880.
Read now
Read now
Noura Nouri & Claus Garbe. (2016) Intralesional immunotherapy as a strategy to treat melanoma. Expert Opinion on Biological Therapy 16:5, pages 619-626.
Read now
Read now
Kevin J Harrington, Igor Puzanov, J. Randolph Hecht, F. Stephen Hodi, Zsolt Szabo, Swami Murugappan & Howard L Kaufman. (2015) Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy. Expert Review of Anticancer Therapy 15:12, pages 1389-1403.
Read now
Read now
Articles from other publishers (13)
Sachin Bhagchandani, Jeremiah A. Johnson & Darrell J. Irvine. (2021) Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants. Advanced Drug Delivery Reviews 175, pages 113803.
Crossref
Crossref
Dejan Vidovic, Gordon A. Simms, Sylvia Pasternak, Mark Walsh, Kevork Peltekian, John Stein, Lucy K. Helyer & Carman A. Giacomantonio. (2021) Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient. Frontiers in Immunology 12.
Crossref
Crossref
Nana Dang, Mark Waer, Ben Sprangers & Yuan Lin. (2020) Intratumoral immunotherapy with anti‐PD‐1 and TLR9 agonist induces systemic antitumor immunity without accelerating rejection of cardiac allografts. American Journal of Transplantation 21:1, pages 60-72.
Crossref
Crossref
Carmen T. Gomez de Leon & Jorge Morales-Montor. 2021. Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives. Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives
33
46
.
O. N. Ganusevich, T. N. Nesterovich, I. V. Fedorkevich & A. S. Yakovenko. (2020) Treatment of Locoregional Recurrences of Skin Melanoma (a Clinical Case). Kuban Scientific Medical Bulletin 27:3, pages 105-112.
Crossref
Crossref
Omid Hamid, Rubina Ismail & Igor Puzanov. (2020) Intratumoral Immunotherapy—Update 2019. The Oncologist 25:3, pages e423-e438.
Crossref
Crossref
Kenneth M. Joyce. 2017. Cutaneous Melanoma: Etiology and Therapy. Cutaneous Melanoma: Etiology and Therapy
91
100
.
María B. Pampena, María M. Barrio, Estefanía P. Juliá, Paula A. Blanco, Erika M. von Euw, José Mordoh & Estrella Mariel Levy. (2017) Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro Analysis of Immune Recruitment and Cytokine Release. Frontiers in Immunology 8.
Crossref
Crossref
Cristina O'Donoghue, Matthew P Doepker & Jonathan S Zager. (2016) Talimogene laherparepvec: overview, combination therapy and current practices. Melanoma Management 3:4, pages 267-272.
Crossref
Crossref
Elisabetta Catalani, Francesca Proietti Serafini, Silvia Zecchini, Simona Picchietti, Anna Maria Fausto, Enrico Marcantoni, Federico Buonanno, Claudio Ortenzi, Cristiana Perrotta & Davide Cervia. (2016) Natural products from aquatic eukaryotic microorganisms for cancer therapy: Perspectives on anti-tumour properties of ciliate bioactive molecules. Pharmacological Research 113, pages 409-420.
Crossref
Crossref
Cristiana Perrotta, Federico Buonanno, Silvia Zecchini, Alessio Giavazzi, Francesca Proietti Serafini, Elisabetta Catalani, Laura Guerra, Maria Cristina Belardinelli, Simona Picchietti, Anna Maria Fausto, Simone Giorgi, Enrico Marcantoni, Emilio Clementi, Claudio Ortenzi & Davide Cervia. (2016) Climacostol reduces tumour progression in a mouse model of melanoma via the p53-dependent intrinsic apoptotic programme. Scientific Reports 6:1.
Crossref
Crossref
Sarah SlootOmar M. RashidAmod A. Sarnaik & Jonathan S. Zager. (2016) Developments in Intralesional Therapy for Metastatic Melanoma. Cancer Control 23:1, pages 12-20.
Crossref
Crossref
Emmanuel Gabriel & Joseph Skitzki. (2015) The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options. Cancers 7:3, pages 1154-1177.
Crossref
Crossref